Clinical trial NCT05065216: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Official title: Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Acute Stroke
Ischemic Stroke
Stroke
Keywords: acute
ischemic
stroke
AIS
tPA
LVO
MT
KLK1
Kallikreins
Lead sponsor: DiaMedica Therapeutics Inc
Sponsor class: INDUSTRY
First posted: 2021-10-04
Enrollment: 728
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Primary purpose: TREATMENT

Brief summary: This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.

Detailed description: This is a Phase 2/3 Adaptive Design, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial). Participants with AIS will be randomized 1:1 to DM199 or placebo. DM199 will be administered as a single intravenous (IV) dose (0.5 μg/kg; not to exceed 50 μg) followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21. The duration of each individual's participation in the study will be approximately 90 days from the time of initial treatment to completion of all study activities.

A formal interim analysis will be conducted after 200 participants complete their Day 90 assessment in Part A. The purposes of this interim analysis are to assess safety, allow early stopping of the study for futility, or continuing the study with a revised final sample up to a maximum of 728 participants.

Eligibility criteria: Inclusion Criteria:

1. Participant is between 18 and 90 years of age inclusive.
2. Participant weight is 40 kg to 166 kg inclusive.
3. Participant to be randomized and treatment initiated within 24 hours of last known normal/AIS stroke onset.
4. Participant has NIHSS ≥5 and ≤15 at approximately the time of randomization. This criterion also applies to participants who meet the following conditions:

   * The participant initially presents with an NIHSS score below 5 but clinically worsens, including cases of progressing stroke / stroke-in-evolution, resulting in a subsequent persistent NIHSS score of ≥5 and ≤15; and
   * Participant meets all other inclusion and exclusion criteria, including repeat brain imaging to rule out hemorrhagic transformation.
5. Participant had a pre-morbid mRS score of 0 to 1 (mRS score prior to AIS) as stated by participant or participant's representative.
6. If participant has received fibrinolytic treatment for AIS within 4.5 hours of last know normal/AIS stoke onset and at least 6 hours after completing fibrinolytic treatment, and the participant meets all of the following criteria:

   * Participant's initial NIHSS score prior to fibrinolytics was ≤15; and
   * At least six hours after fibrinolytics, the participant has NIHSS score of ≥5 and ≤15 with a persistent deficit; and
   * The participant's NIHSS score showed less than a 4-point improvement, or worsened, after receiving fibrinolytics; and
   * Participant meets all other inclusion and exclusion criteria including repeat brain imaging to rule out hemorrhagic transformation.
7. Participant and/or legally authorized representative is able to provide informed consent.
8. Participant is willing and able to comply with the study protocol, in the Investigator's judgment.

Exclusion Criteria:

1. At screening, or with repeat imaging (see Inclusion 4 and 6), participant has imaging confirmed hemorrhage stroke.
2. Participant has image findings with symptomatic large vessel occlusion at one or more of the following locations: Intracranial carotid I/T/L or M1 segment MCA, vertebral or basilar artery (BA).
3. Participant has large core of established infarction defined as ASPECTS 0-5.
4. Participant has or will receive MT for their current AIS.
5. Participant has suspected or confirmed extracranial arterial dissection.
6. Participant has imaging findings and/or symptoms consistent with a brain stem or cerebellar stroke. Posterior cerebral artery strokes without any associated brain stem or cerebellar involvement are allowable.
7. Participant has any recorded SBP \<100 mmHg or MAP \<65 mmHg; MAP = DBP + \[1/3 (SBP - DBP)\] (measured with noninvasive BP cuff type monitor) after stroke symptom onset and prior to randomization.
8. Participant is currently prescribed angiotensin-converting enzyme inhibitor (ACEi) and is unable or unwilling to convert to another antihypertensive pharmacological treatment through Day 29 ±1 day (8 days after last treatment).
9. Participant is currently prescribed an ACEi, and the last dose of the ACE inhibitor medication is reported to have been taken \< 24 hours before start of IV study drug infusion as stated by participant or participant's representative.
10. Participant has a history of clinically significant allergic reactions such as angioedema or anaphylaxis requiring hospitalization.
11. Participant has a diagnosis or suspected diagnosis of hereditary angioedema (HAE) or is taking or prescribed medications commonly used as prophylaxis/treatment of HAE, such as C1-esterase inhibitors (Cinryze, Berinert, Ruconest, Haegarda), Danazol, kallikrein inhibitors (Ecallantide, Berotralstat, Lanadelumab), Bradykinin B2 Receptor Antagonists (Icatibant), or other medication designed to influence the kallikrein-kinin system.
12. Life expectancy estimated at ≤1 year prior to enrollment.
13. Participant has clinical evidence of an active infection at the time of enrollment requiring parenteral treatment or hospitalization to monitor or manage the infection.

    NOTE: Treatment of uncomplicated infections with oral antibiotics would not be an exclusion (for example, the treatment of uncomplicated urinary tract infections or sinus infections with oral antibiotics would not be exclusionary).
14. Participant has known alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency).
15. Participant is pregnant or nursing. NOTE: Participants who agree to stop nursing may be considered for inclusion at the discretion of the Investigator.
16. Participants of child-bearing potential must agree to use medically acceptable contraceptive measures to prevent pregnancy. All participants of childbearing potential (defined as sexually mature participants who have had menses within the preceding 24 months and have not undergone permanent sterilization methods such as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.) must have a negative serum pregnancy test performed locally at screening. Participants of childbearing potential must agree not to attempt to become pregnant or undergo in vitro fertilization. If participating in sexual activity that could lead to pregnancy, participants must use 2 reliable methods (1 per partner is acceptable) of contraception simultaneously while receiving protocol-specified medication and during the study follow-up period.

    Participants participating in sexual activity must agree to use, or for their partner to use highly effective birth control methods (those with a failure rate of less than 1% per year when used consistently and correctly) until they have completed the study (after the Day 90 visit). Such methods include:
    * Combined (estrogen and progesterone containing) hormonal oral, intravaginal, or transdermal contraception associated with the inhibition of ovulation
    * Progesterone-only oral, injectable, or implantable hormonal contraception associated with the inhibition of ovulation
    * Intrauterine device (IUD)
    * Intrauterine hormone-releasing system (IUS)
    * Bilateral tubal occlusion
    * Vasectomized partner
    * Sexual abstinence Participants who are not of reproductive potential (who have been postmenopausal for more than 24 consecutive months or have undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.) are not required to use contraception.

    Participants are prohibited from sperm donation. NOTE: A negative serum pregnancy test will be documented during screening if a participant is of child-bearing potential.
17. Participant is currently participating in or has participated in a study using an investigational device or drug or received an investigational drug or investigational use of a licensed drug within 30 days prior to screening.
18. Participant does not have sufficient venous access for infusion of study treatment or blood sampling.
19. Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits.
20. Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results.

Primary outcomes:
measure: Stroke Recovery
timeFrame: Day 90
Secondary outcomes:
measure: Effect on Disability
timeFrame: Day 90
measure: Independent Function
timeFrame: Day 90
measure: Mortality Rate
timeFrame: Day 90
measure: Neurological Outcome
timeFrame: Day 90
measure: Functional Independence
timeFrame: Day 90
measure: AIS Recurrence
timeFrame: Day 90
Other outcomes:
Locations:
city: Fairhope
country: United States
facility: Gulf Health Hospitals d/b/a Thomas Hospital
state: Alabama
city: Glendale
country: United States
facility: Glendale Adventist Medical Center d/b/a Adventist Health Glendale
state: California
city: Los Angeles
country: United States
facility: Kaiser Permanente Los Angeles Medical Center
state: California
city: Los Angeles
country: United States
facility: Ronald Reagan UCLA Medical Center
state: California
city: Torrance
country: United States
facility: Memorialcare Long Beach Medical Center
state: California
city: Atlantis
country: United States
facility: HCA Florida - JFK Medical Center
state: Florida
city: Sarasota
country: United States
facility: Sarasota Memorial Hospital
state: Florida
city: Tampa
country: United States
facility: Tampa General Hospital (TGH) - The Stroke Center
state: Florida
city: Peoria
country: United States
facility: OSF HealthCare Saint Francis Medical Center
state: Illinois
city: Munster
country: United States
facility: Community Hospital - MacArthur
state: Indiana
city: Wichita
country: United States
facility: Ascension Via Christi Hospitals Wichita Inc.
state: Kansas
city: Baltimore
country: United States
facility: Medstar Franklin Square Medical Center
state: Maryland
city: Grand Rapids
country: United States
facility: Trinity Health Grand Rapids Hospital
state: Michigan
city: Minneapolis
country: United States
facility: Abbott Northwestern Hospital
state: Minnesota
city: Bridgeton
country: United States
facility: SSM Health DePaul Hospital - St Louis
state: Missouri
city: Albuquerque
country: United States
facility: The University of New Mexico - School of Medicine
state: New Mexico
city: New York
country: United States
facility: Northwell Health Physician Partners - Neurology at Lenox Hill
state: New York
city: Dayton
country: United States
facility: Miami Valley Hospital
state: Ohio
city: Dayton
country: United States
facility: The Clinical Neuroscience Institute
state: Ohio
city: Toledo
country: United States
facility: Mercy Health - St. Vincent Medical Center
state: Ohio
city: Oklahoma City
country: United States
facility: The University of Oklahoma Health Sciences Center
state: Oklahoma
city: Tulsa
country: United States
facility: Ascension St. John
state: Oklahoma
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
city: Philadelphia
country: United States
facility: The Hospital of the University of Pennsylvania
state: Pennsylvania
city: Greenville
country: United States
facility: Prisma Health-Greenville Memorial Hospital
state: South Carolina
city: Chattanooga
country: United States
facility: Erlanger Hospital
state: Tennessee
city: Chattanooga
country: United States
facility: Chattanooga Center for Neurologic Research
state: Tennessee
city: Johnson City
country: United States
facility: Ballad Health
state: Tennessee
city: Houston
country: United States
facility: Houston Methodist Neurological Institute
state: Texas
city: Houston
country: United States
facility: Memorial Hermann Hospital, Texas Medical Center
state: Texas
city: Vancouver
country: Canada
facility: Vancouver General Hospital
state: British Columbia
city: Kutaisi
country: Georgia
facility: West Georgia Medical Center LTD
city: Tbilisi
country: Georgia
facility: Israel-Georgia Medical Research Clinic-Healthycore LTD
city: Tbilisi
country: Georgia
facility: New Hospitals LTD
city: Tbilisi
country: Georgia
facility: Pineo Medical Ecosystem LTD
city: Tbilisi
country: Georgia
facility: JSC K. Eristavi National Center of Experimental and Clinical Surgery
Study officials:
affiliation: University of Pennsylvania
name: Scott Kasner, MD
role: PRINCIPAL_INVESTIGATOR
References: